On 23 June 2026 the UK's National Institute for Health and Care Excellence (NICE) issued final draft guidance recommending teplizumab (brand name Tzield) for NHS use in England and Wales.
It is the first disease-modifying drug for type 1 diabetes: it delays the symptomatic stage 3 of the disease by about three years on average.
It is for adults and children aged 8 and over who are in stage 2, the pre-symptomatic stage.
Made by Sanofi, it is given as a single 14-day course of daily intravenous infusions.
Type 1 diabetes is autoimmune: the body destroys insulin-making beta cells in the pancreas. Stage 1: autoantibodies, normal sugar. Stage 2: autoantibodies with abnormal sugar, no symptoms. Stage 3: symptoms and lifelong insulin. Teplizumab acts at stage 2.
Simple Analogy: It does not put out the fire; it holds it back for a few years.
Assesses clinical and cost effectiveness and recommends which treatments the NHS should fund; set up in 1999
UK medicines regulator; licenses a drug as safe and effective before NICE appraises it
GS Paper 3 > Science and Technology > Biotechnology and health
A laboratory-made antibody that binds one specific target; teplizumab targets CD3 on T cells
Cells of the pancreatic islets of Langerhans that produce insulin